A more efficient method to generate integration-free human iPS cells

• Published in: Nature methods Vol. 8; no. 5; pp. 409 - 412
• Main Authors: Okita, Keisuke, Matsumura, Yasuko, Sato, Yoshiko, Okada, Aki, Morizane, Asuka, Okamoto, Satoshi, Hong, Hyenjong, Nakagawa, Masato, Tanabe, Koji, Tezuka, Ken-ichi, Shibata, Toshiyuki, Kunisada, Takahiro, Takahashi, Masayo, Takahashi, Jun, Saji, Hiroh, Yamanaka, Shinya
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.05.2011; Nature Publishing Group
• Subjects: 631/1647/1511; 631/532/2064/2158; 631/532/2435; Analysis; Antigens; Asian Continental Ancestry Group - genetics; Bioinformatics; Biological Microscopy; Biological Techniques; Biomedical and Life Sciences; Biomedical Engineering/Biotechnology; brief-communication; Cell Culture Techniques - methods; Cellular biology; Electroporation; Gene Expression Profiling; Gene Frequency; Genetic Vectors; Genomics; Health aspects; Histocompatibility antigens; HLA Antigens - genetics; HLA histocompatibility antigens; Humans; Induced Pluripotent Stem Cells - cytology; Induced Pluripotent Stem Cells - immunology; Induced Pluripotent Stem Cells - metabolism; Leukocytes; Life Sciences; Methods; Physiological aspects; Plasmids; Plasmids - genetics; Proteomics; Stem cells; Tissue Donors; Tumor suppressor genes; Japan
• ISSN: 1548-7091; 1548-7105
• DOI: 10.1038/nmeth.1591

Human induced pluripotent stem cells are generated with episomal plasmid vectors at increased efficiency using non-transforming L-Myc and knockdown of p53. Also in this issue, Chen et al . report defined conditions for human cell reprogramming and culture. We report a simple method, using p53 suppression and nontransforming L-Myc, to generate human induced pluripotent stem cells (iPSCs) with episomal plasmid vectors. We generated human iPSCs from multiple donors, including two putative human leukocyte antigen (HLA)-homozygous donors who match ∼20% of the Japanese population at major HLA loci; most iPSCs are integrated transgene-free. This method may provide iPSCs suitable for autologous and allologous stem-cell therapy in the future.